Global Head External Supply Cell & Gene
Dr Weiler joined Novartis beginning of 2019 he has more than 22 years of experience in the CMO, CDMO and Pharmaceutical Drug Substance and Drug Product industry.
In his current role, he has overall responsibility for Novartis global external strategic supply programs in Cell & Gene Therapy. Before joining, Novartis Andreas was the global Business Unit Head for Lonza’s Cell & Gene Therapy and Bio conjugate (ADC) business. During this time, Lonza evolved to be the leading CMO in the Cell & Gene Therapy industry by building the largest Cell & Gene Therapy facility in Houston Texas, the acquisition of PharmaCell in the Netherlands plus numerous strategic partnerships differentiating Lonza not only from a global manufacturing footprint but also from an innovation perspective.
Based on his 20 years of manufacturing experience he is also involved in the automation of patient specific processes to make those therapies available for more and more patients globally.